Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman

Neurochemical Research

Volumn 28, Issue 11, 2003, Pages 1705-1713

  Selkoe, Dennis J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Neurodegeneration; Proteolysis; Synaptic plasticity; Therapeutics

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; LIFE CYCLE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE INJURY; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SENILE PLAQUE; SYNAPTIC TRANSMISSION; TARGET CELL;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; BRAIN CHEMISTRY; HUMANS; NERVE DEGENERATION; NEURONAL PLASTICITY; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0142021035     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026065122854     Document Type: Review

References (59)

1. Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., and Katzman, R. 1991. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30:572-580.
2. Cummings, B. J., Pike, C. J., Shankle, R., and Cotman, C. W. 1996. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 17:921-933.
3. Small, D. H., Mok, S. S., and Bornstein, J. C. 2001, Alzheimer's disease and Abeta toxicity: From top to bottom. Nat. Rev. Neurosci. 2:595-598.
4. Davies, C. A., Mann, D. M., Sumpter, P. Q., and Yates, P. O. 1987. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 78:151-164.
5. Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., and Davies, P. 1995. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16:285-298; discussion 298-304.
6. Sze, C. I., Troncoso, J. C., Kawas, C., Mouton, P., Price, D. L., and Martin, L. J. 1997. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:933-944.
7. Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., and Mucke, L. 1999. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96:3228-3233.
8. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. 2000. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20:4050-4058.
9. Naslund, J., Haroutunian, V., Mohs, R., Davis, K. L., Davies, P., Greengard, P., and Buxbaum, J. D. 2000. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
10. Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., and Roher, A. E. 1996. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271:4077-4081.
11. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:860-866.
12. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., and Rogers, J. 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:853-862.
13. Whitson, J. S., Selkoe, D. J., and Cotman, C. W. 1989. Amyloid β protein enhances the survival of hippocampal neurons in vitro. Science 243:1488-1490.
14. Pike, C. J., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. 1991. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:311-314.
15. Yankner, B. A., Duffy, L. K., and Kirschner, D. A. 1990. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides. Science 250:279-282.
16. Lorenzo, A. and Yankner, B. 1994. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91:12243-12247.
17. Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M., and Nakazato, Y. 1989. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by β protein immunostain. Acta Neuropathol. 77:314-319.
18. Tagliavini, F., Giaccone, G., Frangione, B., and Bugiani, O. 1988. Preamyloid deposits in the cerebral cortex of patients with Alzheimers disease and nondemented individuals. Neurosci. Lett. 93:191-196.
19. Haass, C., Schlossmacher, M., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D., and Selkoe, D. 1992. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322-325.
20. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M. G., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D. J., Lieberburg, I., and Schenk, D. 1992. Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature 359:325-327.
21. Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X., McKay, D. M., Tintner, R., Frangione, B., and Younkin, S. G. 1992. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258:126-129.
22. Selkoe, D. J. and Podlisny, M. B. 2002. Deciphering the genetic basis of alzheimer's disease. Pages 67-99, in Lander, E., Page, D., and Lifton, R. (eds.), Annual Review of Genomics and Human Genetics, Palo Alto, CA, Annual Reviews.
23. Selkoe, D. J. and Schenk, D. 2003. Pages 545-584, in Blaschke, T. F., Insel, P. A., and Loh, H. H. Alzheimer's Disease: Molecular understanding Predicts Amyloid-Based Therapeutics, Vol. 43, Palo Alto, CA, Annual Reviews.
24. Selkoe, D. 2001. Clearing the brain's amyloid cobwebs. Neuron 32:177-180.
25. Podlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydel, R. E., Teplow, D. B., and Selkoe, D. J. 1995. Aggregation of secreted amyloid β-protein into SDS-stable oligomers in cell culture. J. Biol. Chem. 270:9564-9570.
26. Walsh, D., Klyubin, I., Fadeeva, J., William K., Cullen, W., Anwyl, R., Wolfe, M., Rowan, M., and Selkoe, D. 2002. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
27. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. 1992. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360:672-674.
28. Cai, X.-D., Golde, T. E., and Younkin, G. S. 1993. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259:514-516.
29. Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, Jr., L., Eckman, C., Golde, T. E., and Younkin, S. G. 1994. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 264:1336-1340.
30. Sisodia, S. S. and Price, D. L. 1998. Mutant genes in familial Alzheimer's disease and transgenic models. Pages 479-505, in Cowan, W. M., Shooter, E.M., Stevens, C. F., and Thompson, R. F. (eds.), Annual Review of Neuroscience, Palo Alto, CA, Annual Reviews.
31. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. 1999. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398:513-517.
32. Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelli, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X.-P., Yin, K.-C., Shafer, J. A., and Gardell, S. J. 2000. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689-694.
33. Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J.-Y., Rahmati, T., Xia, W., Selkoe, D. J., and Wolfe, M. S. 2000. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell Biol. 2:428-434.
34. Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K., and Martoglio, B. 2002. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296:2215-2218.
35. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. J., and Saido, T. C. 2001. Metabolic regulation of brain Abeta by neprilysin. Science 292:1550-1552.
36. Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M., Rosner, M. R., Safavi, A., Hersh, L. B., and Selkoe, D. J. 1998. Insulin degrading enzyme regulates the level of monomeric amyloid β-protein extracellularly via degradation and oligomeriztion. J. Biol. Chem. 273:32730-32738.
37. Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., and Selkoe, D. J. 2000. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20:1657-1665.
38. Farris, W., Change, Y., Mansourian, S., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., and Guenette, S. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein and the APP intracellular domain in vivo. Proc. Natl. Acad. Sci. USA 100:4162-4167.
39. Eckman, E. A., Reed, D. K., and Eckman, C. B. 2001. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276:24540-24548.
40. Bertram, L., Blacker, D., Mullin, K., Keeney, D., Jones, J., Basu, S., Yhu, S., McInnis, M. G., Go, R. C., Vekrellis, K., Selkoe, D. J., Saunders, A. J., and Tanzi, R. E. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290:2302-2303.
41. Feuk, L., Prince, J., Graziano, C., Blennow, K., and Brookes, A. 2002. Multiple genes may be involved in explaining the linage peak on chromosome 10: Evidence rom SNPbased association studies. Neurobiol. Ag. Abstr. 23(1S):S424.
42. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vendevert, C., S, Wogulis, M., Yednock, T., Games, D., and Seubert, P. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
43. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
44. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98:8850-8855.
45. Matsuoka, Y., Saito, M., LaFrancois, J., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., Lemere, C., and Duff, K. 2003. Novel therapeutic approaches for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23:29-33.
46. Poduslo, J. F., Curran, G. L., Haggard, J. J., Biere, A. L., and Selkoe, D. J. 1997. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol. Dis. 4:27-34.
47. Zlokovic, B. V. 1996. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 59:1483-1497.
48. Selkoe, D. J. 2002. Alzheimer's disease is a synaptic failure. Science 298:789-791.
49. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., and Rydel, R. E. 1993. Evidence for excito-protective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10:243-254.
50. Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M. B., Teplow, D. B., Haass, C., Seubert, P., Koo, E. H., and Selkoe, D. J. 1997. Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272:7977-7982.
51. Podlisny, M. B., Walsh, D. M., Amarante, P., Ostaszewski, B. L., Stimson, E. R., Maggio, J. E., Teplow, D. B., and Selkoe, D. J. 1998. Oligomerization of endogenous and synthetic amyloid β-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37:3602-3611.
52. Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., and Selkoe, D. J. 2000. Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain. Biochemistry 39:10831-10839.
53. Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., and Selkoe, D. J. 1997. Degradation of amyloid β-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272:6641-6646.
54. Urbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K. H., Duff, K., Stanley, H. E., Irizarry, M. C., and Hyman, B. T. 2002. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99:]13990-13995.
55. Craft, D. L., Wein, L. M., and Selkoe, D. J. 2002. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma. Bull. Math. Biol. 64:1011-1031.
56. Kimberly, W. T., LaVoie, M. J., Ostaszewski, B. L., Ye, W., Wolfe, M. S., and Selkoe, D. J. 2003. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastric, Aph-1 and Pen-2. Proc. Natl. Acad. Sci. USA 100:6882-6887.
57. Rogers, J., Webster, S., Lue, L.-F., Brachova, L., Civin, W. H., Emmerling, M., Shivers, B., Walker, D., and McGeer, P. 1996. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging 17:681-686.
58. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216.
59. Cotman, C. W. and Anderson, A. J. 2000. The brain's microenvironment, early functional loss, and the conversion to Alzheimer's disease. Ann. N Y Acad. Sci. 924:112-116.